[Polatuzumab vedotin治疗复发或难治性DLBCL: 1例报告]。

Q3 Medicine
Daniele Contin, Roberto Sartori, Sara Berti, Alida Sartorello, Carlo Giovanni Doroldi
{"title":"[Polatuzumab vedotin治疗复发或难治性DLBCL: 1例报告]。","authors":"Daniele Contin, Roberto Sartori, Sara Berti, Alida Sartorello, Carlo Giovanni Doroldi","doi":"10.1701/4556.45580","DOIUrl":null,"url":null,"abstract":"<p><p>Diffuse large B-cell lymphomas (DLBCLs) represent one of the most common and aggressive forms of non-Hodgkin lymphoma (NHL), characterized by rapid B-cell growth and a significantly high risk of relapse or refractoriness. The clinical course for these patients is long and complicated with a sometimes dismal prognosis, and the therapeutic approach must include effective and innovative chemotherapeutic treatments. The therapeutic strategies for DLBCLs in recent years has seen considerable pharmacological enrichment, including drug-conjugated antibodies such as polatuzumab vedotin. Indeed, this drug has demonstrated its efficacy even in the age-unfit elderly patient, providing a good safety and tolerability profile. Specifically, is described the case of an elderly patient with relapsed/refractory DLBCL with extra-nodal and bone disease presentation, treated second-line with polatuzumab vedotin in combination with rituximab and bendamustine. This combination resulted in a complete clinical and metabolic response while preserving excellent drug tolerance during treatment and improving the patient's quality of life.</p>","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"116 9","pages":"530-535"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Polatuzumab vedotin in the treatment of relapsed or refractory DLBCL: a case report].\",\"authors\":\"Daniele Contin, Roberto Sartori, Sara Berti, Alida Sartorello, Carlo Giovanni Doroldi\",\"doi\":\"10.1701/4556.45580\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Diffuse large B-cell lymphomas (DLBCLs) represent one of the most common and aggressive forms of non-Hodgkin lymphoma (NHL), characterized by rapid B-cell growth and a significantly high risk of relapse or refractoriness. The clinical course for these patients is long and complicated with a sometimes dismal prognosis, and the therapeutic approach must include effective and innovative chemotherapeutic treatments. The therapeutic strategies for DLBCLs in recent years has seen considerable pharmacological enrichment, including drug-conjugated antibodies such as polatuzumab vedotin. Indeed, this drug has demonstrated its efficacy even in the age-unfit elderly patient, providing a good safety and tolerability profile. Specifically, is described the case of an elderly patient with relapsed/refractory DLBCL with extra-nodal and bone disease presentation, treated second-line with polatuzumab vedotin in combination with rituximab and bendamustine. This combination resulted in a complete clinical and metabolic response while preserving excellent drug tolerance during treatment and improving the patient's quality of life.</p>\",\"PeriodicalId\":20887,\"journal\":{\"name\":\"Recenti progressi in medicina\",\"volume\":\"116 9\",\"pages\":\"530-535\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Recenti progressi in medicina\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1701/4556.45580\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recenti progressi in medicina","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1701/4556.45580","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

弥漫性大b细胞淋巴瘤(DLBCLs)是非霍奇金淋巴瘤(NHL)最常见和侵袭性的形式之一,其特点是b细胞生长迅速,复发或难治性风险高。这些患者的临床过程漫长而复杂,有时预后不佳,治疗方法必须包括有效和创新的化疗治疗。近年来,dlbcl的治疗策略已经有了相当大的药理学丰富,包括药物偶联抗体,如polatuzumab vedotin。事实上,这种药物即使在年龄不适合的老年患者中也证明了其有效性,提供了良好的安全性和耐受性。具体来说,描述了一例伴有淋巴结外和骨骼疾病表现的复发/难治性DLBCL老年患者,用polatuzumab vedotin联合利妥昔单抗和苯达莫司汀进行二线治疗。这种组合产生了完全的临床和代谢反应,同时在治疗期间保持了良好的药物耐受性,并改善了患者的生活质量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[Polatuzumab vedotin in the treatment of relapsed or refractory DLBCL: a case report].

Diffuse large B-cell lymphomas (DLBCLs) represent one of the most common and aggressive forms of non-Hodgkin lymphoma (NHL), characterized by rapid B-cell growth and a significantly high risk of relapse or refractoriness. The clinical course for these patients is long and complicated with a sometimes dismal prognosis, and the therapeutic approach must include effective and innovative chemotherapeutic treatments. The therapeutic strategies for DLBCLs in recent years has seen considerable pharmacological enrichment, including drug-conjugated antibodies such as polatuzumab vedotin. Indeed, this drug has demonstrated its efficacy even in the age-unfit elderly patient, providing a good safety and tolerability profile. Specifically, is described the case of an elderly patient with relapsed/refractory DLBCL with extra-nodal and bone disease presentation, treated second-line with polatuzumab vedotin in combination with rituximab and bendamustine. This combination resulted in a complete clinical and metabolic response while preserving excellent drug tolerance during treatment and improving the patient's quality of life.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Recenti progressi in medicina
Recenti progressi in medicina Medicine-Medicine (all)
CiteScore
0.90
自引率
0.00%
发文量
143
期刊介绍: Giunta ormai al sessantesimo anno, Recenti Progressi in Medicina continua a costituire un sicuro punto di riferimento ed uno strumento di lavoro fondamentale per l"ampliamento dell"orizzonte culturale del medico italiano. Recenti Progressi in Medicina è una rivista di medicina interna. Ciò significa il recupero di un"ottica globale e integrata, idonea ad evitare sia i particolarismi della informazione specialistica sia la frammentazione di quella generalista.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信